Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 2/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6536808 | 0.80 | BCHE (0.55) | OPRM1OPRD1OPRK1 | |
| SCHEMBL28230034 | 0.80 | TDP1 (0.67) | TDP1L3MBTL1HRH1CYP2A6CHRNA7 | |
| SCHEMBL16606321 | 0.79 | CHRNB2 (0.56) | CYP2A6CHRNA7 | |
| SCHEMBL8199625 | 0.79 | TDP1 (0.61) | TDP1L3MBTL1HRH1CYP2A6CHRNA7 | |
| SCHEMBL29485675 | 0.78 | TDP1 (0.80) | TDP1L3MBTL1HRH1CYP2A6CHRNA7 | |
| SCHEMBL724788 | 0.78 | TDP1 (0.80) | TDP1L3MBTL1HRH1CYP2A6CHRNA7 | |
| SCHEMBL11329185 | 0.77 | CYP2A6 (0.59) | TDP1L3MBTL1HRH1CYP2A6CHRNA7 | |
| SCHEMBL29485634 | 0.76 | HRH1 (0.81) | TDP1L3MBTL1HRH1CYP2A6CHRNA7 | |
| SCHEMBL2845851 | 0.76 | HRH1 (0.81) | TDP1L3MBTL1HRH1CYP2A6CHRNA7 | |
| SCHEMBL8658187 | 0.76 | HRH1 (0.81) | TDP1L3MBTL1HRH1CYP2A6CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020151564-A1 | Methods for inhibiting immunostimulatory DNA associated responses | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2002-10-17 | — | — | US | claimed |
| US-6399630-B1 | 2-ALKOXY-6-HALO-9-AMINOACRIDINES; BLOCKING ANTI-APOPTOTIC EFFECT OF CPG-ODN AND CPG-ODN-INDUCED SECRETION OF IL-6; HIGHLY SPECIFIC; AUTOIMMUNE DISEASE, ARTHRITIS, LUPUS, INFLAMMATORY BOWEL DISEASE | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2002-06-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151564-A1 | Methods for inhibiting immunostimulatory DNA associated responses | IRF3, STING1, DNA2 | TDP1 336/4885L3MBTL1 3426/4885HRH1 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.